Trial reportFrontiers in endocrinology2026
Maternal thyroid function and subsequent markers of insulin resistance in pregnant women with polyendocrine metabolic ovarian syndrome.
Trial report in Frontiers in endocrinology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
7 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Objectives: Low maternal free thyroxine (fT4) levels have been associated with markers of insulin resistance and gestational diabetes. Our primary aim was to investigate whether maternal thyroid function was associated with subsequent insulin resistance in pregnant women with polyendocrine metabolic ovary syndrome (PMOS, previously known as PCOS). Methods: In this Results: At baseline, the women had a mean body mass index (BMI) of 28.9 and HOMA-IR 3.2, and none had overt hypothyroidism. We found significant inverse associations between the change in TSH during pregnancy and post-load glucose at gw19, as well as fasting glucose at gw36, i.e. the smaller increase in maternal TSH, the higher subsequent maternal glucose levels. Furthermore, lower maternal fT4 levels were significantly associated with higher subsequent insulin/HOMA-IR levels, and the change in TSH was also inversely associated with HOMA-IR at gw32. All associations were independent of treatment with metformin or placebo. Conclusions: In this exploratory
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.